Asuragen is seeking outstanding Master degree-level scientists who can work as part of an R&D group that is charged with creating innovative amplification-based assays for the detection and quantification of nucleic acid and/or protein biomarkers. This high-impact position will help expand Asuragen’s molecular diagnostics portfolio that currently influences over 15 million patient management decisions each year.
The Scientist position will work within Asuragen’s R&D team to develop and optimize sample-to-answer workflows for nucleic acid-based tests. This role will support technology initiatives to enable novel multiplexed PCR assays that can resolve multiple classes of DNA, RNA, and protein markers. Assays are designed using fast-and-simple methods that can be broadly deployed in kitted diagnostic products and integrate reagents, instrumentation, and analysis algorithms and software. Successful candidates will join a fast-growing company of nearly 160 employees focused on enhancing patient care through the development of cutting-edge diagnostic assays in disease areas spanning genetic disorders and cancer.
A Master degree
or equivalent Bachelor degree plus relevant experience) in biology, chemistry, biomedical engineering, or related field
A strong track record of independence, innovation, and productivity
Excellent written and verbal communication skills
A passion for improving patient care through diagnostic technologies, particularly in genetics and oncology
Demonstrated ability to independently design and implement experimental plans or processes to support objectives within the organization
Preferable Experience and Skills:
3 years industry laboratory expertise in multiple technologies/fields, including multiplexed PCR methods
Application of novel amplification methods, including immuno-PCR and related techniques, for the sensitive detection or quantification of multimodal biomarkers in clinical specimens
Experience writing and contributing to research grant applications
NIH or other)
Ability to train and mentor co-workers on equipment and procedures and assisting with data analysis and interpretation
Experience with capillary electrophoresis instrumentation or nanopore-based sequencing would be a plus
Experience in developing regulated molecular diagnostic tests, especially FDA-approved tests, is a plus
Expert in one or more technology areas and used as a resource by colleagues to develop similar skills
Asuragen is a molecular diagnostics company that is using genomics to drive better patient management through best-in-class clinical testing solutions. The Company enlists a breadth of technologies and talent to discover, develop and commercialize diagnostic products and services with efficiency and flexibility for internal projects and partners in biotechnology and pharmaceutics. Asuragen is located in Austin, Texas, which is consistently ranked in the top 10 of “best of” lists of US cities and offers a superior lifestyle along with top-notch technology, educational, and business benefits. The Company provides a competitive salary, medical, dental, disability and life insurance, a 401
k) plan with company matching, an employee bonus plan, and a tuition reimbursement plan.
Website : http://www.asuragen.com
We are a global diagnostic products company that delivers the answers patients deserve. We believe better answers start with the right questions. That’s why we are always striving to develop diagnostic products that build knowledge and understanding of complex clinical questions. A Reputation You Can Rely On. Asuragen’s application of our deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. Every year, Asuragen’s products and technologies impact over 15 million patient tests in 70+ countries. Progress is Mandatory. We continually strive to advance and transform the science of personalized medicine, demonstrated in part by over 50 peer-reviewed publications in the past 5 years. With so many unmet clinical needs across oncology and genetic testing, we know time is of the essence. Patients need answers and labs need a diagnostic partner they can rely on.